WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

*Arshan Aqeel Abdullah, Dr. Mohammed Fawzi Alqanbar and Dr. Mohammed Shnain Ali

ABSTRACT

Introduction: Hodgkin Lymphoma is a hematolymphoid malignancy that can affect any age group worldwide. Both genders can be affected by Hodgkin lymphoma with slight predilection for male gender. Involvement by Hodgkin lymphoma range from single node to wide spread disease. Although it has a successful story to response to conventional therapies, there still a proportion of patients who are refractory to primary therapy and those who relapse after prolong courses of therapy. The aim of study is to Show PD-L1 expression in Iraqi Hodgkin lymphoma. PD-L1 expression and Hodgkin lymphoma clinicopathologic status should be correlated. PD-L1 expression in primary and refractory/relapsed patients. Method: This cross-sectional study gathered thirty paraffin blocks from thirty Hodgkin lymphoma patients from the histo-pathological lab. Two 5-?m portions per block. One segment was stained with hematoxylin and eosin and the other with monoclonal rabbit anti-Human PD-L1 E1L3N[R] antibody. The positive threshold was 1%, hence the case was termed negative when <1% of tumour cells expressed PD-L1, low when 1-49%, and high when > 50%. Negative, weak, moderate, and severe staining were rated. Results: 90% of patients had positive PD-L1 and 10% had negative. PD-L1 expression was high (73.3%) and low (16.7%) in those staining positively. PD-L1 staining correlated with age (P< 0.05), whereas gender, Hodgkin lymphoma histologic subtypes, clinical stage, initial disease, refractory/relapsed condition, and tumour cell CD30 and CD15 expression did not. Conclusion: Most Hodgkin Lymphoma tumour cells expressed PD-L1. Older people expressed more PD-L1, but other clinicopathologic markers did not correlate. Novel PD-L1 medication should provide equivalent results in initial disease and refractory/relapsed patients.